Early Treatment Delays Multiple Sclerosis Progression

	Tweet

Early treatment significantly delays the initial progression of multiple sclerosis, according to research that will be presented at the American Academy of Neurology 58th Annual Meeting in San Diego, Calif., April 1 - 8, 2006.

Evidence suggests that immunomodulatory drugs (drugs that control the immune system) initiated early in the disease course of multiple sclerosis delays the disease’s progression.

Researchers from Canada, Europe, and Israel collaborated on the study, which demonstrated a 50-percent reduction in the risk for clinically definite MS among patients taking the drug interferon beta-1b.

In this study, patients with a first clinical event suggestive of MS were randomized to treatment with interferon beta-1b or placebo control groups. Interferons are small soluble proteins or glycoproteins that alter immune responses.

The drug was injected at .25 mg every other day to 292 patients who were identified as having their first demyelinating event (loss of myelin, the insulation that surrounds the nerve fiber and aids the transmission of nerve impulses) and with MS-associated brain lesions identified through magnetic resonance imaging (MRI). Both treatment and control groups (176 patients in placebo group) were treated until clinically definite MS was diagnosed or they had been followed for two years. Of those taking the drug, 28 percent were diagnosed with MS after two years, compared to 45 percent of those taking the placebo.

“This shows that there is a remarkable benefit for treatment even after only one episode of MS-like symptoms” said Mark S. Freedman, MD, FAAN, of the University of Ottawa in Ottawa, Canada.

The study was supported by funding from Schering AG, Germany, the maker of interferon beta-1b.

The American Academy of Neurology, an association of more than 19,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer disease, epilepsy, multiple sclerosis, Parkinson disease, and stroke.

http://www.aan.com

RELATED STORIES:
Sound training rewires dyslexic children’s brains for reading   Stem cells may protect brain, nervous system   Calorie Restriction May Prevent Alzheimer’s Disease   Elderly drivers have higher crash rates in non problematic environments than other drivers   Experimental Therapy May Lead to Macular Degeneration   Researchers: Pay More Attention to Epilepsy   High Levels of Vitamin D In the Body May Decrease the Risk of Multiple Sclerosis   Researchers link herpes to Alzheimer’s disease   Opioids recommended for elderly with chronic pain   Study Shows Obese Nurses More Stressed, Less Active   High BP worsens impact of stroke on brain function   Executive function and Alzheimer’s disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]